Tempest Therapeutics
TPST
37 hedge funds and large institutions have $16.4M invested in Tempest Therapeutics in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 11 closing their positions.
94% more call options, than puts
Call options by funds: $93K | Put options by funds: $48K
28% more capital invested
Capital invested by funds: $12.9M → $16.4M (+$3.57M)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
12% less funds holding
Funds holding: 42 → 37 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$642K |
| 2 |
Two Sigma Advisers
New York
|
+$232K |
| 3 |
Two Sigma Investments
New York
|
+$157K |
| 4 |
JP Morgan Chase
New York
|
+$132K |
| 5 |
Bank of New York Mellon
New York
|
+$99.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.61M |
| 2 |
B
Bpifrance
Maisons Alfort, Cedex,
France
|
-$875K |
| 3 |
AIC
AWM Investment Company
New York
|
-$324K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$189K |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$87K |
TPST Hedge Fund Activity: Q4 2020 in Review
37 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2020, worth a combined $16.4M — up 28% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TPST and 6 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Barclays, adding an estimated $642K. The largest seller was Great Point Partners, cutting an estimated $1.61M.
- 37 institutional investors held Tempest Therapeutics (TPST) as of Q4 2020, down from 42 in Q3 2020.
- Funds reported $16.4M of Tempest Therapeutics stock for Q4 2020, up 28% quarter-over-quarter.
- 6 funds opened new Tempest Therapeutics positions in Q4 2020 and 11 closed out, a net change of -5 holders.
- The largest Tempest Therapeutics buyer in Q4 2020 was Barclays, an estimated $642K added.
- The largest Tempest Therapeutics seller in Q4 2020 was Great Point Partners, an estimated $1.61M sold.
Based on aggregated 13F filings for Q4 2020.